Skip to main content
EMA Logo
  • Medicines
    Medicines

    • Search
    • Download
    • What we publish and when
    • Medicines under evaluation
    • National registers
    • Medicines for use outside the EU
  • Human regulatory
    Human regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Herbal products
  • Veterinary regulatory
    Veterinary regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    Committees

    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    News & events

    • News and press releases
    • Events
    • What's new
    • Committee highlights
    • Therapeutic areas: latest updates
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    Partners & networks

    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Academia
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    About us

    • What we do
    • Who we are
    • How we work
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Support to research
    • Contact
    • Legal
    • Glossaries
    • Search tips
    • FAQs
    • Brexit: UK withdrawal from EU

COVID-19 pandemic

All info here

QUICK LINKS

  • Latest updates
  • Vaccines
  • Treatments
  • Guidance for developers and companies
  • Outcome of the PRAC review of COVID-19 Vaccine Janssen
    COVID-19 - updates on Janssen slider
    COVID-19 |Vaccines

    Outcome of the PRAC review of COVID-19 Vaccine Janssen

  • Outcome of the PRAC review of COVID-19 Vaccine Janssen
    COVID-19 - updates on Janssen slider
    COVID-19 |Vaccines

    Outcome of the PRAC review of COVID-19 Vaccine Janssen

    EMA’s safety committee (PRAC) finds possible link to very rare cases of unusual blood clots with low blood platelets but overall benefit-risk remains positive

  • EMA continues to monitor COVID-19 vaccine AstraZeneca
    prac conclusion
    COVID-19 |Vaccines

    EMA continues to monitor COVID-19 vaccine AstraZeneca

  • EMA continues to monitor COVID-19 vaccine AstraZeneca
    prac conclusion
    COVID-19 |Vaccines

    EMA continues to monitor COVID-19 vaccine AstraZeneca

    EMA to provide further context on risk of very rare blood clots with low blood platelets that occurred after vaccination with Vaxzevria

  • PRAC highlights April 2021
    PRAC highlights
    MEDICINES |COMMITTEES

    PRAC highlights April 2021

  • PRAC highlights April 2021
    PRAC highlights
    MEDICINES |COMMITTEES

    PRAC highlights April 2021

    Outcomes from the April meeting cover all aspects of the risk management of the use of medicines, including COVID-19 vaccines

  • Development, evaluation and monitoring of COVID-19 vaccines
    COVID-19 vaccines tier 2 slider
    COVID-19 |VACCINES

    Development, evaluation and monitoring of COVID-19 vaccines

  • Development, evaluation and monitoring of COVID-19 vaccines
    COVID-19 vaccines tier 2 slider
    COVID-19 |VACCINES

    Development, evaluation and monitoring of COVID-19 vaccines

    Read about how EMA is ensuring vaccines for COVID-19 meet the highest standards of quality, safety & efficacy while their development and approval is sped up due to the public health emergency.

Search for medicines
Search for information on human, veterinary or herbal medicines.
What's new
Find all the latest news and updates published on this website in one place.
FAQs
Find answers to the most frequently asked questions we receive.

Latest news

  • List item
    20/04/2021 COVID-19

    COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

    EMA confirms overall benefit-risk remains positive At its meeting of 20 April 2021, EMA’s safety committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19...

  • List item
    16/04/2021

    Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 13-15 April 2021

    CVMP opinions on veterinary medicinal products The Committee adopted by consensus positive opinions for type II variation applications concerning quality-related changes for: Comfortis (grouped variations) Purevax Rabies Purevax RCP FeLV, Purevax...

  • List item
    15/04/2021 COVID-19

    EMA starts review of VIR-7831 for treating patients with COVID-19

    EMA is reviewing currently available data on the use of the monoclonal antibody VIR-7831 (also known as GSK4182136) in the treatment of patients with COVID-19. EMA is starting this review to support national authorities who may decide on the use of...

  • List item
    14/04/2021 COVID-19

    AstraZeneca’s COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets

    EMA continues to monitor very rare blood clots with low blood platelets that occurred after vaccination with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) . In line with a request from the EU’s Commissioner for Health and Food Safety following...

  • List item
    14/04/2021 COVID-19

    COVID-19 Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues

    As announced last week, EMA’s safety committee (PRAC) is reviewing very rare cases of unusual blood clots that occurred in the United States following the use of Janssen’s COVID-19 vaccine. The type of blood clot reported, cerebral venous sinus...

  • List item
    14/04/2021

    IT systems intermittently unavailable from 16 to 18 April 2021

    All European Medicines Agency (EMA) information technology (IT) systems apart from the corporate website ( www.ema.europa.eu ) will be intermittently unavailable from 18:00 on Friday 16 April to 11:00 on Sunday 18 April 2021 (Central European Summer...

  • Load more news

Information for

Patients and carers
Featured news and updates for patients and carers
Healthcare professionals
Featured news and updates for healthcare professionals, including doctors, nurses and pharmacists
Animal health professionals
Featured news and updates for animal health professionals and users of veterinary medicines such as pet owners
Pharmaceutical industry
Featured news and updates for pharmaceutical industry stakeholders active in the human and veterinary medicines fields
Media
Featured news and updates for journalists with a professional interest in the development and availability of medicines in the European Union
Academia
Featured news and updates for European academics and researchers in the field of medicine development

Key content

  • List item

    Product emergency hotline

  • List item

    UK’s withdrawal from the EU

  • List item

    PRIME: Priority medicines

  • List item

    Pharmacovigilance (safety monitoring)

  • List item

    Data on medicines

  • List item

    Clinical data publication

  • List item

    Careers

Services & databases

  • List item

    Account Management portal

  • List item

    eSubmission

  • List item

    EudraVigilance (human)

  • List item

    EU Veterinary Medicinal Product Database

  • List item

    Suspected adverse drug reactions database

  • List item

    Clinical data

  • List item

    SPOR data management services

  • List item

    Service Desk

  • List item

    IRIS platform

  • List item

    Public register of parallel distribution notices

  • List item

    European Vaccination Information Portal

How does EMA work?

  • List item

    What we do

  • List item

    Our role in authorisation of medicines

  • List item

    Who we are

  • List item

    Our scientific experts

  • List item

    How we work

  • List item

    What we publish

Product emergency hotline
outside working hours
About
  • Who we are
  • Human regulatory
  • Veterinary regulatory
  • Committees
Ask EMA
  • Send a question
  • FAQs
  • Access to documents
Links
  • Legal
  • Privacy
  • Complaints
  • Contacts
  • Glossary
  • Search tips
  • Business hours and holidays
Contact

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

For delivery address, see:
How to find us

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.
RSS feed Twitter YouTube LinkedIn
© 1995-2021 European Medicines Agency
European Union agencies network
European Union agencies network
An agency of the European Union
European Union flag